Phencyclidine decreases binding capacity of serotonin2 receptor in vitro

Toshitaka Nabeshima, Y. Noda, H. Furukawa, T. Kameyama

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We have investigated that effects of phencyclidine (PCP) on [3H]-spiperone binding to synaptic membrane in the presence of sulpiride to distinguish serotonin (5-HT2) receptor from dopamine2 receptor. The amount of [3H]-spiperone specific binding was larger in the frontal and occipital cortices than in other areas. PCP strongly inhibited the [3H]spiperone binding at the concentration of 20 nM. Mescaline also weakly inhibited that, but not other hallucinogenic reagents such as methamphetamine, cyclazocine, scopolamine and atropine at the same concentration. In the presence of 20 n3M PCP a significant decrease of Bmax and no change of Kd in the [3H]-spiperone specific binding was observed. Present results are consistent with the hypothesis that PCP may be a potent and selective agonist at 5-HT2 binding sites. Although PCP known as hallucinogen interacts strongly with 5-HT2 receptor, it is still too premature to draw any conclusions regarding a possible relationship between 5-HT binding and hallucinogenic potency.

Original languageEnglish
Pages (from-to)175-186
Number of pages12
JournalResearch Communications in Substances of Abuse
Volume5
Issue number3
Publication statusPublished - 01-12-1984
Externally publishedYes

Fingerprint

Spiperone
Phencyclidine
Cyclazocine
Mescaline
Serotonin 5-HT2 Receptor Agonists
Serotonin 5-HT2 Receptors
Hallucinogens
Occipital Lobe
Synaptic Membranes
Sulpiride
Scopolamine Hydrobromide
Methamphetamine
Frontal Lobe
Atropine
Serotonin
Binding Sites
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)

Cite this

@article{c65fc4f6862a4d34b4fae42e639be6e5,
title = "Phencyclidine decreases binding capacity of serotonin2 receptor in vitro",
abstract = "We have investigated that effects of phencyclidine (PCP) on [3H]-spiperone binding to synaptic membrane in the presence of sulpiride to distinguish serotonin (5-HT2) receptor from dopamine2 receptor. The amount of [3H]-spiperone specific binding was larger in the frontal and occipital cortices than in other areas. PCP strongly inhibited the [3H]spiperone binding at the concentration of 20 nM. Mescaline also weakly inhibited that, but not other hallucinogenic reagents such as methamphetamine, cyclazocine, scopolamine and atropine at the same concentration. In the presence of 20 n3M PCP a significant decrease of Bmax and no change of Kd in the [3H]-spiperone specific binding was observed. Present results are consistent with the hypothesis that PCP may be a potent and selective agonist at 5-HT2 binding sites. Although PCP known as hallucinogen interacts strongly with 5-HT2 receptor, it is still too premature to draw any conclusions regarding a possible relationship between 5-HT binding and hallucinogenic potency.",
author = "Toshitaka Nabeshima and Y. Noda and H. Furukawa and T. Kameyama",
year = "1984",
month = "12",
day = "1",
language = "English",
volume = "5",
pages = "175--186",
journal = "Research Communications in Substances of Abuse",
issn = "0193-0818",
publisher = "PJD Publications Ltd",
number = "3",

}

Phencyclidine decreases binding capacity of serotonin2 receptor in vitro. / Nabeshima, Toshitaka; Noda, Y.; Furukawa, H.; Kameyama, T.

In: Research Communications in Substances of Abuse, Vol. 5, No. 3, 01.12.1984, p. 175-186.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phencyclidine decreases binding capacity of serotonin2 receptor in vitro

AU - Nabeshima, Toshitaka

AU - Noda, Y.

AU - Furukawa, H.

AU - Kameyama, T.

PY - 1984/12/1

Y1 - 1984/12/1

N2 - We have investigated that effects of phencyclidine (PCP) on [3H]-spiperone binding to synaptic membrane in the presence of sulpiride to distinguish serotonin (5-HT2) receptor from dopamine2 receptor. The amount of [3H]-spiperone specific binding was larger in the frontal and occipital cortices than in other areas. PCP strongly inhibited the [3H]spiperone binding at the concentration of 20 nM. Mescaline also weakly inhibited that, but not other hallucinogenic reagents such as methamphetamine, cyclazocine, scopolamine and atropine at the same concentration. In the presence of 20 n3M PCP a significant decrease of Bmax and no change of Kd in the [3H]-spiperone specific binding was observed. Present results are consistent with the hypothesis that PCP may be a potent and selective agonist at 5-HT2 binding sites. Although PCP known as hallucinogen interacts strongly with 5-HT2 receptor, it is still too premature to draw any conclusions regarding a possible relationship between 5-HT binding and hallucinogenic potency.

AB - We have investigated that effects of phencyclidine (PCP) on [3H]-spiperone binding to synaptic membrane in the presence of sulpiride to distinguish serotonin (5-HT2) receptor from dopamine2 receptor. The amount of [3H]-spiperone specific binding was larger in the frontal and occipital cortices than in other areas. PCP strongly inhibited the [3H]spiperone binding at the concentration of 20 nM. Mescaline also weakly inhibited that, but not other hallucinogenic reagents such as methamphetamine, cyclazocine, scopolamine and atropine at the same concentration. In the presence of 20 n3M PCP a significant decrease of Bmax and no change of Kd in the [3H]-spiperone specific binding was observed. Present results are consistent with the hypothesis that PCP may be a potent and selective agonist at 5-HT2 binding sites. Although PCP known as hallucinogen interacts strongly with 5-HT2 receptor, it is still too premature to draw any conclusions regarding a possible relationship between 5-HT binding and hallucinogenic potency.

UR - http://www.scopus.com/inward/record.url?scp=0021737631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021737631&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0021737631

VL - 5

SP - 175

EP - 186

JO - Research Communications in Substances of Abuse

JF - Research Communications in Substances of Abuse

SN - 0193-0818

IS - 3

ER -